12 completed, 7 terminated, 6 recruiting, 5 active not recruiting. 26 Phase 1, 15 Phase 2, 1 Early Phase 1, 1 Not applicable.
Follow NHL: new trials by email Literature Review of NHL trials Research Report on NHL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma HSK47977 - NHL | Phase 1 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 110 | 2025-08-28 | 2025-12-19 |
| A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System BITR2101 - NHL, Cutaneous T Cell Lymphoma | Phase 1 | Not yet recruiting | Boston Immune Technologies and Therapeutics | 37 | 2025-08-01 | 2025-07-08 |
| CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma CMOP±R - NHL | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 197 | 2024-07-08 | 2026-09-09 |
| A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS FD-001 - AML, NHL | Phase 1 | Recruiting | Chengdu FenDi Pharmaceutical Co., Ltd. | 72 | 2024-03-11 | 2024-12-17 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) CLN-978 - NHL, NHL, Relapsed, Adult | Phase 1 | Terminated | Cullinan Therapeutics Inc. | 3 | 2023-05-31 | 2026-10-22 |
| Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies SYNCAR-001, STK-009, Cyclophosphamide - CLL/SLL, NHL | Phase 1 | Active not recruiting | Synthekine | 36 | 2023-04-23 | 2026-07-10 |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL ARI-0001, Axi-cel - NHL, DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | University Medical Center Groningen | 340 | 2022-10-18 | 2026-10-05 |
| A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL BN102 - CLL/SLL, NHL | Phase 1 / Phase 2 | Withdrawn | BioNova Pharmaceuticals (Shanghai) LTD. | 2022-07-01 | 2023-03-24 | |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL HMPL-760 - CLL/SLL, NHL | Phase 1 | Withdrawn | Hutchmed | 2022-02-15 | 2023-02-21 | |
| First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML ETH-155008 - NHL, Leukemia | Phase 1 | Terminated | Shengke Pharmaceuticals Pty Ltd | 9 | 2021-06-29 | 2023-10-11 |
| A Study of IGN002 for Refractory NHL IGN002 - NHL | Phase 1 | Withdrawn | Spectrum Pharmaceuticals, Inc | 2021-01-01 | 2022-03-11 | |
| Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. anti-CD19 CAR NK - NHL | Early Phase 1 | Unknown | Xinqiao Hospital of Chongqing | 9 | 2020-12-17 | 2020-11-20 |
| FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL FT596, Rituximab - NHL, Non Hodgkin Lymphoma | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 7 | 2020-09-22 | 2024-07-09 |
| Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients IM19 CAR-T Cells - NHL | Phase 1 / Phase 2 | Recruiting | Beijing Immunochina Medical Science & Technology Co., Ltd. | 52 | 2020-06-04 | 2020-12-08 |
| A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients No intervention - NHL | Completed | Stichting Hemato-Oncologie voor Volwassenen Nederland | 250 | 2020-03-17 | 2026-10-13 | |
| Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy - Follicular Lymphoma, Non-Hodgkin's Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2019-08-22 | 2026-03-03 |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma DA-EPOCH, Rituximab, CHOP - Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 132 | 2019-08-05 | 2026-10-26 |
| A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant Hyperbaric oxygen - AML, NHL | Phase 2 | Active not recruiting | University of Rochester | 64 | 2019-02-28 | 2026-07-20 |
Showing 20 of 38. Sign in to see all of them.
Lymphoma, Non-Hodgkin (15) · Lymphoma, Follicular (6) · Lymphoma, Large B-Cell, Diffuse (6) · Multiple Myeloma (6) · Hematologic Neoplasms (5) · Hodgkin Disease (4) · Leukemia (4) · Lymphoma (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Dendritic Cell Sarcoma, Interdigitating (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myeloid, Acute (3) · Lymphoma, B-Cell (3) · Graft vs Host Disease (2) · Lymphoma, Mantle-Cell (2)
Neoplasms by Histologic Type (27) · Hemic and Lymphatic Diseases (26) · Neoplasms (26) · Lymphatic Diseases (24) · Immune System Diseases (23) · Immunoproliferative Disorders (23) · Lymphoproliferative Disorders (23) · Lymphoma (19) · Hematologic Diseases (16) · Blood Protein Disorders (7) · Cardiovascular Diseases (7) · Hemorrhagic Disorders (7) · Hemostatic Disorders (7) · Leukemia (7) · Lymphoma, B-Cell (7)
Rituximab (5) · Cyclophosphamide (3) · fludarabine (3) · Biopsy (2) · Electrocardiography (2) · Positron-Emission Tomography (2) · acalabrutinib (2) · veltuzumab (2) · AZD5153 (1) · Acetaminophen (1) · Antibodies, Monoclonal (1) · Antilymphocyte Serum (1) · Azacitidine (1) · Biological Therapy (1) · Cyclosporine (1)
National Cancer Institute (NCI) (5) · Gilead Sciences (3) · Beijing Immunochina Medical Science & Technology Co., Ltd. (2) · Stichting Hemato-Oncologie voor Volwassenen Nederland (2) · Acerta Pharma BV (1) · Amgen (1) · AstraZeneca (1) · BioNova Pharmaceuticals (Shanghai) LTD. (1) · Boston Immune Technologies and Therapeutics (1) · Cambridge Antibody Technology (1) · Chengdu FenDi Pharmaceutical Co., Ltd. (1) · Cullinan Therapeutics Inc. (1) · Dana-Farber Cancer Institute (1) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1) · Duke University (1)
United States (24) · China (7) · Australia (3) · France (3) · Netherlands (3) · Italy (2) · Poland (2) · Belgium (1) · Canada (1) · Germany (1) · Greece (1) · Israel (1) · Japan (1) · Spain (1) · United Kingdom (1)
Christopher J Melani, M.D. (2) · William Wegener, MD, PhD (2) · Charles A. Linker, M.D. (1) · David Porter, MD (1) · Dr.Veronika Bachanova, MD, PhD (1) · Elizabeth Hexner, MD (1) · Haiwen Huang (1) · Hongmei Jing, MD (1) · Ian Flinn, MD, PhD (1) · James Zhang (1) · Jeffrey Skolnik, MD (1) · John Timmerman (1) · Laura Beane-Freeman (1) · Lea Burke (1)
PMID 21173095, PMID 26389849, PMID 26858124, PMID 28062705, PMID 32286905, PMID 34253597, PMID 34309174, PMID 34687939, PMID 37295816, PMID 37486616, PMID 37864885, PMID 37882668, PMID 40249860, PMID 40802906, PMID 41411486, PMID 41824279
2017 (2), P01CA111412 (1)